Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041483 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT00041483 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 530 participants.
The verdict
NCT00041483, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
Interventions
- DRUG Anecortave Acetate 15 mg sterile suspension
- OTHER Photodynamic Therapy (PDT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2002-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041483
The ClinicalTrials.gov registry entry for NCT00041483 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anecortave Acetate 15 mg sterile suspension is the first listed.
NCT00041483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041483 about?
NCT00041483 is a clinical study titled "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD". The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
What is the current status of trial NCT00041483?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2002-06. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00041483?
The interventions under investigation include: Anecortave Acetate 15 mg sterile suspension (DRUG), Photodynamic Therapy (PDT) (OTHER).
Who is sponsoring clinical trial NCT00041483?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.